Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Robert E. Landry net worth and biography

Robert Landry Biography and Net Worth

CFO of Regeneron Pharmaceuticals

Robert E. Landry, 57, has been Executive Vice President, Finance since January 2019 and Chief Financial Officer since October 2013. From September 2013 to December 2018, he served as Senior Vice President, Finance. Previously, Mr. Landry served as Senior Vice President, Treasurer, at Pfizer Inc. from October 2012 to August 2013 and Senior Vice President – Finance, Pfizer’s Diversified Business, from October 2009 to October 2012. Prior to those roles, Mr. Landry held a number of positions at Wyeth, which was acquired by Pfizer Inc. in October 2009, including Treasurer and Principal Corporate Officer from 2007 to 2009, Director of Pharmaceutical Marketing and Sales of Wyeth’s Australian affiliate from 2006 to 2007, and Chief Financial Officer of Wyeth’s Australian and New Zealand affiliates from 2004 to 2006. Mr. Landry holds a B.B.A. in Accounting from the University of Notre Dame.

What is Robert E. Landry's net worth?: The estimated net worth of Robert E. Landry is at least $22.25 million as of August 23rd, 2023. Mr. Landry owns 31,699 shares of Regeneron Pharmaceuticals stock worth more than $22,247,943 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Landry may own. Learn More about Robert E. Landry's net worth.
How do I contact Robert E. Landry?: The corporate mailing address for Mr. Landry and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on Robert E. Landry's contact information.
Has Robert E. Landry been buying or selling shares of Regeneron Pharmaceuticals?: Robert E. Landry has not been actively trading shares of Regeneron Pharmaceuticals in the last ninety days. Most recently, Robert E. Landry sold 223 shares of the business's stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $844.00, for a transaction totalling $188,212.00. Following the completion of the sale, the chief financial officer now directly owns 31,699 shares of the company's stock, valued at $26,753,956. Learn More on Robert E. Landry's trading history.
Who are Regeneron Pharmaceuticals' active insiders?: Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Regeneron Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 27 times. They sold a total of 107,995 shares worth more than $105,556,492.64. The most recent insider tranaction occured on August, 28th when CFO Christopher R Fenimore sold 5,680 shares worth more than $6,846,274.40. Insiders at Regeneron Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.
Information on this page was last updated on 8/28/2024.

Robert E. Landry Insider Trading History at Regeneron Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/23/2023	Sell	223	$844.00	$188,212.00	31,699
3/27/2023	Sell	183	$821.70	$150,371.10	32,929
2/6/2023	Sell	752	$788.88	$593,237.76	32,105
2/3/2023	Sell	739	$764.50	$564,965.50	32,105
10/17/2022	Sell	358	$739.50	$264,741.00	28,744
4/11/2022	Sell	1,862	$734.06	$1,366,819.72	28,744
4/8/2022	Sell	325	$737.79	$239,781.75	28,744
4/1/2022	Sell	316	$695.81	$219,875.96
3/29/2022	Sell	2,683	$687.90	$1,845,635.70
3/21/2022	Sell	300	$693.00	$207,900.00
3/17/2022	Sell	83	$686.00	$56,938.00
12/13/2021	Sell	116	$662.50	$76,850.00
12/10/2021	Sell	781	$666.42	$520,474.02
11/17/2021	Sell	681	$645.08	$439,299.48
8/9/2021	Sell	364	$617.83	$224,890.12
8/4/2020	Sell	696	$654.46	$455,504.16	23,973
7/21/2020	Sell	391	$647.58	$253,203.78	27,473
7/14/2020	Sell	579	$640.50	$370,849.50	23,973
7/8/2020	Sell	1,160	$639.66	$742,005.60	33,973
6/29/2020	Sell	400	$612.57	$245,028.00	24,334
6/9/2020	Sell	4,271	$606.59	$2,590,745.89
4/20/2020	Sell	3,250	$566.94	$1,842,555.00	28,373
4/17/2020	Sell	991	$557.68	$552,660.88	28,373
4/15/2020	Sell	853	$518.49	$442,271.97	27,873
4/13/2020	Sell	828	$509.79	$422,106.12	27,873
4/7/2020	Sell	696	$497.52	$346,273.92	27,373
4/2/2020	Sell	105	$495.88	$52,067.40	25,092
2/25/2020	Sell	214	$449.01	$96,088.14	25,973
9/6/2017	Sell	663	$498.60	$330,571.80	10,099
9/5/2017	Sell	189	$501.06	$94,700.34	10,099
8/31/2017	Sell	427	$493.43	$210,694.61	9,099
8/23/2017	Sell	468	$476.45	$222,978.60	9,099
8/8/2017	Sell	526	$472.19	$248,371.94	9,099

Robert E. Landry Buying and Selling Activity at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Today's Range

Now: $701.85

$700.83

$717.61

50 Day Range

MA: $821.00

$701.85

$1,016.53

2 Week Range

Now: $701.85

$693.00

$1,211.20

Volume

1,889,979 shs

Average Volume

568,354 shs

Market Capitalization

$77.13 billion

P/E Ratio

17.37

Dividend Yield

N/A

Beta

0.08

First JFK… next Elon?

From Porter & Company | Ad